PMID- 21299897
OWN - NLM
STAT- MEDLINE
DCOM- 20110613
LR  - 20240109
IS  - 1476-4598 (Electronic)
IS  - 1476-4598 (Linking)
VI  - 10
DP  - 2011 Feb 7
TI  - Curcumin: A review of anti-cancer properties and therapeutic activity in head and 
      neck squamous cell carcinoma.
PG  - 12
LID - 10.1186/1476-4598-10-12 [doi]
AB  - Curcumin (diferuloylmethane) is a polyphenol derived from the Curcuma longa 
      plant, commonly known as turmeric. Curcumin has been used extensively in 
      Ayurvedic medicine for centuries, as it is nontoxic and has a variety of 
      therapeutic properties including anti-oxidant, analgesic, anti-inflammatory and 
      antiseptic activity. More recently curcumin has been found to possess anti-cancer 
      activities via its effect on a variety of biological pathways involved in 
      mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigenesis 
      and metastasis. Curcumin has shown anti-proliferative effect in multiple cancers, 
      and is an inhibitor of the transcription factor NF-kappaB and downstream gene 
      products (including c-myc, Bcl-2, COX-2, NOS, Cyclin D1, TNF-alpha, interleukins and 
      MMP-9). In addition, curcumin affects a variety of growth factor receptors and 
      cell adhesion molecules involved in tumor growth, angiogenesis and metastasis. 
      Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
      worldwide and treatment protocols include disfiguring surgery, platinum-based 
      chemotherapy and radiation, all of which may result in tremendous patient 
      morbidity. As a result, there is significant interest in developing adjuvant 
      chemotherapies to augment currently available treatment protocols, which may 
      allow decreased side effects and toxicity without compromising therapeutic 
      efficacy. Curcumin is one such potential candidate, and this review presents an 
      overview of the current in vitro and in vivo data supporting its therapeutic 
      activity in head and neck cancer as well as some of the challenges concerning its 
      development as an adjuvant chemotherapeutic agent.
FAU - Wilken, Reason
AU  - Wilken R
AD  - Department of Surgery, VA Greater Los Angeles Healthcare System, West Los 
      Angeles, CA, USA.
FAU - Veena, Mysore S
AU  - Veena MS
FAU - Wang, Marilene B
AU  - Wang MB
FAU - Srivatsan, Eri S
AU  - Srivatsan ES
LA  - eng
GR  - R21 CA116826-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20110207
PL  - England
TA  - Mol Cancer
JT  - Molecular cancer
JID - 101147698
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antioxidants)
RN  - IT942ZTH98 (Curcumin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemistry/pharmacology/*therapeutic use
MH  - Antioxidants/chemistry/pharmacology/therapeutic use
MH  - Apoptosis/drug effects
MH  - Carcinoma, Squamous Cell/*drug therapy/pathology
MH  - Curcumin/chemistry/pharmacology/*therapeutic use
MH  - Head and Neck Neoplasms/*drug therapy/pathology
MH  - Humans
PMC - PMC3055228
EDAT- 2011/02/09 06:00
MHDA- 2011/06/15 06:00
PMCR- 2011/02/07
CRDT- 2011/02/09 06:00
PHST- 2010/08/04 00:00 [received]
PHST- 2011/02/07 00:00 [accepted]
PHST- 2011/02/09 06:00 [entrez]
PHST- 2011/02/09 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
PHST- 2011/02/07 00:00 [pmc-release]
AID - 1476-4598-10-12 [pii]
AID - 10.1186/1476-4598-10-12 [doi]
PST - epublish
SO  - Mol Cancer. 2011 Feb 7;10:12. doi: 10.1186/1476-4598-10-12.